The number of newly diagnosed classical Hodgkin lymphoma cases across the US, France, Germany, Italy, Spain, the UK, Japan and China (8MM) is expected to rise from 27,000 in 2025 to 28,000 by 2035, according to GlobalData. The company’s latest report, Hodgkin Lymphoma: Epidemiology Report and Forecast, projects an annual… Read More
R&D teams don’t need another chatbot. They need a team that can act on their behalf, guided by the scientists who know the science best. The future of R&D removes the toil of day-to-day work and connects the data scattered across your systems and teams. In this webinar, taking place… Read More
The Drug Discovery Innovators & Investors (DDII) UK Conference has announced a new panel, From Rules to Runway: How UK Regulation Can Accelerate or Obstruct Drug Development, examining how organisations can navigate the UK regulatory environment while supporting innovation and accelerating the development of new therapies. The conference takes place… Read More
Australian radiopharmaceuticals spinout, Skopos Bio, has launched with an AUD$12 million (US$8.3 million) seed round, led by a global investor syndicate. The company was founded by three clinical and translational scientists from Melbourne’s Peter MacCallum Cancer Centre (Peter Mac), who continue to treat patients and lead research:… Read More
The latest episode of the DDW Sitting Down With vodcast is sponsored by ProBio, and our guest is Derek Chen, who Multimedia Editor Megan Thomas interviewed on how AI is transforming antibody drug discovery, from identifying and prioritising candidates to early developability assessment, experimental validation and the integration of discovery,… Read More
Breye Therapeutics has closed an over-subscribed €67.5 million Series A financing round. The round was co-led by new investor Mission BioCapital and existing investor Novo Holdings, with participation from existing investor Sound Bioventures and additional new investors including the Ljungström family office, Innovestor Life Science, EIFO, Catalyze… Read More
Seventeen new companies will now benefit from BioInnovation Institute (BII)’s innovation platform, which helps companies attract capital and bring promising technologies to market. The innovation house is providing a total of around €9.5 million. Following the announcement of a new €736 million from the Novo Nordisk Foundation to the BII,… Read More
The US Food and Drug Administration (FDA) has given the go-ahead to Genentech’s Gazyva (obinutuzumab) in adult and paediatric patients two years of age and older. It is approved to reduce the risk of relapse in patients with frequently relapsing or steroid dependent childhood-onset idiopathic nephrotic syndrome… Read More
GSK has entered an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) from Chimagen Biosciences, a privately held biotechnology company. GSK plans to develop and commercialise the asset for multiple myeloma, with the programme expected to enter Phase I trials in 2027. TCEs have shown… Read More
Kevan Shokat has been named the 2026 Stephenson Global Prize Laureate, receiving $1 million for his pioneering contributions to pancreatic cancer research. His discoveries helped transform decades of scientific thinking about KRAS, one of cancer’s most important and historically difficult-to-target drivers, and usher in a new generation… Read More
The pharmacological behaviour of drugs is determined not only by their intrinsic properties but also by the sensitivity of the biological systems in which they are evaluated. Variations in receptor density and signal transduction efficiency can significantly influence observed drug responses, complicating the translation of in vitro findings to in… Read More
Scarlet Therapeutics has entered into an agreement with the Defense Advanced Research Projects Agency (DARPA) to advance the development of smart red blood cells (SRBCs). Scarlet will lead a multidisciplinary consortium to develop SRBCs in a programme worth up to $14 million. The agreement builds… Read More
Magnitude Biosciences, a specialist contract research organisation (CRO) and Durham University spinout, has secured £1.3 million ($1.7 million) in funding to accelerate the commercialisation of VivoScan, its proprietary in vivo high-throughput screening (HTS) platform. VivoScan is unique in providing HTS for drug discovery in a… Read More
An open letter from the chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi has urged European governments to create conditions that attract investment in next-generation medicines. They argue that Europe is losing ground to global competition, with over $600 billion in… Read More
This digital summit, hosted by DDW and supported by Sino Biological, explores the advances and challenges taking place within the field of immuno-oncology. Featuring expert presentations and a panel discussion, the summit will explore topics such as how to tackle cancer drug resistance, personalised medicine, cytotoxic therapy in the immunotherapy… Read More
A new agreement grants Novo a global exclusive license to Nanexa’s PharmaShell atomic layer deposition (ALD) drug delivery technology platform for certain therapeutic peptide drugs in indications including obesity, type 2 diabetes and other cardiometabolic diseases. The collaboration includes development of long-acting injectable formulations with different administration-frequency… Read More
